Scopus by Title (Ref)
Articles that cite the referenced work, matched by title from the Scopus database.
Anti-inflammatory effects of curcumin carbon dots in an animal model of demyelination induced by lysolecithin
Nanoscale Advances
17 March 2026
DaeiRezaei L.
Open Access
Targeted Drug Delivery in Animal Models of Demyelination: The Role of Plant-Based Nanoparticles with a Focus on Multiple Sclerosis
Molecular Neurobiology
January 2026
Ebrahimbabaei A.
Curcumin as Neuroprotective Agent
Flavonoids for Neurological Disorders Advances and Future Prospects
1 January 2026
Rizvi N.
Recent Advances in Curcumin Drug Delivery Systems Based on Nano Compounds and Their Therapeutic Application
Advanced Therapeutics
January 2026
Tahvilian M.
Intranasal adipose-derived stem cells mitigate cuprizone-induced demyelination in mouse corpus callosum by modulating oligodendrocyte and microglial marker expression: histological and ultrastructural insights
Journal of Molecular Histology
October 2025
Mohamed N.M.
White Matter in Crisis: Oligodendrocytes and the Pathophysiology of Multiple Sclerosis
Cells
September 2025
García-Domínguez M.
Open Access
Evaluation of the neuroprotective effects of Korean Ginseng root extract in an experimental model of multiple sclerosis
Marmara Medical Journal
30 May 2025
Donmez M.O.
Open Access
The Role of Oligodendrocyte Lineage Cells in the Pathogenesis of Alzheimer’s Disease
Neurochemical Research
February 2025
Liu X.
Curcumin ameliorates astrocyte inflammation through AXL in cuprizone-induced mice
Toxicology and Applied Pharmacology
January 2025
Zhang W.
Open Access
The ameliorative effects of curcumin nanomicelle on testicular damage in the mouse model of multiple sclerosis
BMC Complementary Medicine and Therapies
December 2024
Koohpeyma F.
Open Access
Role of Plant Phytochemicals: Resveratrol, Curcumin, Luteolin and Quercetin in Demyelination, Neurodegeneration, and Epilepsy
Antioxidants
November 2024
Grabarczyk M.
Open Access
Antioxidant Therapies in the Treatment of Multiple Sclerosis
Biomolecules
October 2024
Jiménez-Jiménez F.J.
Open Access
Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities
Biomedicine and Pharmacotherapy
August 2024
Li H.
Open Access
Mechanistic insight of curcumin: a potential pharmacological candidate for epilepsy
Frontiers in Pharmacology
2024
Khatoon S.
Open Access
Curcumin Nanoformulations in Neurodegenerative Diseases
Curcumin and Neurodegenerative Diseases from Traditional to Translational Medicines
1 January 2024
Kakkar V.
Insights Into the Role of Copper in Neurodegenerative Diseases and the Therapeutic Potential of Natural Compounds
Current Neuropharmacology
2024
Zhong G.
All Open Access, Green
Curcuminoids with Antineurodegenerative Properties: Current Trends and Future Perspectives
Curcumin and Neurodegenerative Diseases from Traditional to Translational Medicines
1 January 2024
dos Santos L.R.
Oligodendrocyte progenitor cells in Alzheimer’s disease: from physiology to pathology
Translational Neurodegeneration
December 2023
Zou P.
Open Access
Curcumin, inflammation, and neurological disorders: How are they linked?
Integrative Medicine Research
September 2023
Garodia P.
Open Access
Curcumin-Based Nanomedicines in the Treatment of Inflammatory and Immunomodulated Diseases: An Evidence-Based Comprehensive Review
Pharmaceutics
January 2023
Laurindo L.F.
Open Access
Total astragalosides promote oligodendrocyte precursor cell differentiation and enhance remyelination in cuprizone-induced mice through suppression of Wnt/β-catenin signaling pathway
Journal of Ethnopharmacology
15 November 2022
Yuan J.
Curcumin-based nanotechnology approaches and therapeutics in restoration of autoimmune diseases
Journal of Controlled Release
August 2022
Rahiman N.
Dual Mechanism of Action of Curcumin in Experimental Models of Multiple Sclerosis
International Journal of Molecular Sciences
August 2022
ELBini-Dhouib I.
Open Access
Therapeutic opportunities for targeting cellular senescence in progressive multiple sclerosis
Current Opinion in Pharmacology
April 2022
Sutter P.A.
TLR4 Associated Signaling Disrupters as a New Means to Overcome HERV-W Envelope-Mediated Myelination Deficits
Frontiers in Cellular Neuroscience
23 November 2021
Göttle P.
Open Access